China Biologic Pharmaceutical (01177.HK): The phase III study results of the combination of Bevacizumab Biosimilar and Anlotinib as first-line treatment for squamous non-small cell lung cancer will be presented at the 2025 ASCO Annual Meeting.

Zhixun Finance APP News, China Biopharmaceuticals (01177.HK) announced that the group has recently announced the latest results of Phase III clinical research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study compared the sequential combination of pembrolizumab injection and chemotherapy followed by anlotinib hydrochloride capsules with bevacizumab injection and chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC). The median progression-free survival (mPFS) in the experimental group was 10.12 months, a 36% reduction in the risk of disease progression compared to the control group.